SCHEMBL5553739

SCHEMBL5553739

NCCCC[C@H](NC(=O)C(F)(F)F)C(=O)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 1/20 0.46
CPB1 P15086 1/20 0.46
CPB2 Q96IY4 1/20 0.46
LTA4H P09960 1/20 0.46
ITGB3 P05106 4/20 0.45
ITGA2B P08514 4/20 0.45
DPP4 P27487 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
SIRT1 Q96EB6 1/20 0.45
SIRT3 Q9NTG7 1/20 0.45
PRSS1 P07477 2/20 0.44
PRSS2 P07478 2/20 0.44
PRSS3 P35030 2/20 0.44
TPSAB1 Q15661 2/20 0.44
TLR2 O60603 2/20 0.43
DPP8 Q6V1X1 1/20 0.43
LNPEP Q9UIQ6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5548318 0.99 ECE1 (0.46) ECE1CPB1CPB2LTA4HITGB3
SCHEMBL5692870 0.85 ITGB3 (0.60) ECE1CPB1CPB2ITGB3ITGA2B
SCHEMBL9086439 0.85 ITGB3 (0.60) ECE1CPB1CPB2ITGB3ITGA2B
SCHEMBL10420029 0.85 TACR1 (0.41)
SCHEMBL6232160 0.84 MME (0.45) ECE1
SCHEMBL30198146 0.84 TACR1 (0.55) ECE1CPB1CPB2ITGB3ITGA2B
Hydrochloric Acid SCHEMBL7284348 0.84 ITGB3 (0.58) ECE1CPB1CPB2ITGB3ITGA2B
Hydrochloric Acid SCHEMBL7284342 0.84 ITGB3 (0.58) ECE1CPB1CPB2ITGB3ITGA2B
SCHEMBL22385105 0.84 TACR1 (0.55) ECE1CPB1CPB2ITGB3ITGA2B
SCHEMBL6140066 0.84 FOLH1 (0.50) ECE1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111773392-B Human serum albumin/oligonucleotide nano-particles and preparation method and application thereof 河南省生物工程技术研究中心 2023-04-07 CN disclosed
US-20070093664-A1 Process for the production of lisinopril ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) 2007-04-26 US disclosed
EP-1513868-B1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS ECZACIBASI OZGUN KIMYASAL (TR) 2006-08-09 EP disclosed
EP-1513868-A1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. (TR) 2005-03-16 EP disclosed
WO-2005010028-A1 ALPHA-AMINO ACID BENZOTHIAZOLYLTHIO ESTER AS INTERMEDIATES FOR MANUFACTURE OF ACE INHIBITORS AND PROCESS FOR PREPARATION THEREOF LUPIN LIMITED (IN) 2005-02-03 WO disclosed
WO-2004000874-A1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS ECZACIBASI OZGUN KIMYASAL URUNLER SANYI VE TI CARET A.S. (TR) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093664-A1 Process for the production of lisinopril ACE, LOX, AGT ECE1 562/4885CPB1 752/4885CPB2 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.